Trial intelligence / Profile preview

Phase 2a safety and pharmacodynamic study of pexidartinib in mild to moderate Alzheimer's disease

2016-000429-38Phase 2Terminated

Sponsor

Plexxikon Inc.

Start

Jul 2016

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1